Join
Live feed
·
PRReleasevia Quantisnow
Rezolute Inc. logo

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

ByQuantisnow·Wall Street's wire, on your screen.
RZLT· Rezolute Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RZLT (Rezolute Inc.) and more on Quantisnow.